Immunochina Pharmaceuticals key facts
as of Oct 2026- Developer of gene cell medicine technology intended for malignant tumor treatment.
- Immunochina Pharmaceuticals is valued at approximately $215.3M as of Oct 2026 (last reported valuation).
- It has raised $45.0M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Cowin Capital, Legend Capital, SJ Jiacheng Investment Management, GF Qianhe, ZGC Science City — 21 tracked in total.
- Status: Privately Held (backing).
Immunochina Pharmaceuticals's last reported valuation, Sep 2020. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch Immunochina Pharmaceuticals: the Monday email on marks, rounds and moves
Immunochina Pharmaceuticals funding rounds
No funding rounds for Immunochina Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Immunochina Pharmaceuticals
21+Immunochina Pharmaceuticals valuation
Immunochina Pharmaceuticals's last reported valuation was $215 million in Sep 2020. No priced round, secondary trade or fund mark has surfaced since.
Immunochina Pharmaceuticals investors
21 investors are on record for Immunochina Pharmaceuticals, including Cowin Capital, Legend Capital, SJ Jiacheng Investment Management and GF Qianhe. By type, the record holds 3 venture capital firms and 2 funds of funds.
About Immunochina Pharmaceuticals
Developer of gene cell medicine technology intended for malignant tumor treatment. The company is devoted to the development of CAR-T technology and immune cell therapy in cancer and immunology research, helping researchers and practitioners find effective ways to combat hematological malignancies.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Employees
- 100
- Website
- imunopharm.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.